Release of Zavzpret In Late July 2023

Release of Zavzpret In Late July 2023

Zavzpret is indicated for the acute treatment of migraine with or without aura in adults. Zavpret would be the first nasal CGRP (calcitonin gene-related peptide) receptor antagonist approved by the FDA. Currently there are several oral CGRP receptor antagonists to treat acute migraine on the market. A nasal spray can offer an alternative treatment for those who cannot tolerate oral medications due to nausea or vomiting. Anticipated launch date is July 2023.

 

If you have any questions or if we may assist you with your workers’ compensation pharmacy needs, please contact us at 800-553-1783 or at pharmacy@carlislemedical.com.

The post Release of Zavzpret In Late July 2023 appeared first on Carlisle Medical.